Stock Price of Alchemist Mining Surge...
STOCK PRICE OF ALCHEMIST MINING SURGE : REMARKABLE PROGRESS CONTINUES
read more
Featured
Remember Malartic? Why Northern Superior Could Be one of the Best Gold Plays Of 2023!
Gold investors have been waiting a long time for a shot at another Malartic and we believe we just struck gold with Northern Superior Resources (TSX-V: SUP) (OTCQX: NSUPF)!
Malartic was a big gold discovery in the province of Quebec which became a mine and the company owning it ended up being acquired for total considerations of C$3.9 billion! Of course, not all mining developers are as rewarding, but when a company is successful in that sector, the reward for investors can be astonishing.
For those investors who missed out on the 1000%++ returns that we have seen repeatedly in that industry, sit back and keep reading because we believe (TSX-V:SUP) (OTCQX: NSUPF) could be just as interesting and its value is currently only C$60M.
What do you get when you combine one of the largest consolidated gold discoveries in Quebec’s rich history and a rapidly rising gold price driven by global economy in a tailspin, possibly, even stronger gains?
Before we get into the 3 catalysts that could make Northern Superior Resources one of the best gold plays of 2023, let’s go over the basics…
This company owns several deposits near each other and has been making headlines with its impressive drill results from the Philibert gold property in Quebec, where it has delineated of gold near surface over a 3-kilometre strike length.
Those deposits, including Philibert, are located in the rapidly emerging Chibougamau gold camp, which hosts the world-class Nelligan deposit. Nelligan was the “Discovery of the year[1]” in 2019. Many believe that the area, The Chibougamau Gold Camp, has the potential to be the next Malartic, as ounces grow and reach a level similar to one of the largest operating gold mines in Canada.
But that’s not all. Northern Superior also has a stellar executive team that has decades of experience in discovering and developing gold projects in Canada and abroad. The team includes Mr. Victor Cantore, Executive Chairman, a seasoned executive whose most recent win has been to take Amex Exploration from C$0.07 to more than C$3.50 per share in less than 2 years. This team is seriously invested. All in all, the insiders own more than 30% of the company and recently took down almost 20% of the $5M equity financing.
And if that’s not enough to convince you to take a look at Northern Superior, consider this: Northern Superior is well-positioned to benefit from the rising gold prices driven by stagflation. Stagflation is a scenario where inflation rises while economic growth slows down, creating a perfect storm for gold demand. As more investors seek a safe haven from currency devaluation and market volatility, central banks around the world keep buying and gold prices are already soaring to new heights.
BREAKING NEWS
TORONTO, ON / ACCESSWIRE / June 6, 2023 / Northern Superior Resources Inc. (“Northern Superior” or the “Company”) (TSXV:SUP) (OTCQX:NSUPF) is pleased to report the final assay results for nine holes completed on the Falcon Gold Zone (“FGZ“) on its large (20km x 15km) 100% owned Lac Surprise property, located within the Chibougamau gold camp, Québec.
Let’s do a quick summary on Northern Superior Resources (TSXV: SUP) :
Company Name: Northern Superior Resources
Ticker: (TSXV: SUP)
Exchange: TSX
Website: https://nsuperior.com
Northern Superior Resources Company Summary:
Northern Superior is a gold exploration company focused on the Chibougamau Gold Camp in Québec, Canada. The Company has consolidated the largest land package in the region, with total land holdings currently exceeding 62,000 hectares. The main properties include Philibert, Lac Surprise, Chevrier and Croteau Est. Northern Superior also owns significant exploration assets in Northern Ontario highlighted by the district scale TPK Project. The Company has indicated its intention to spin off the TPK Project, which could provide immediate benefit for shareholders.
Without further ado, the 3 catalysts that could make Northern Superior Resources the gold play of 2023:
- #1 The next Canadian Malartic
- #2 The Executive Team
- #3 Stagflation and Its Effect on Gold Prices.
Don’t miss this chance to consider Northern Superior While it is on the ground floor of one of the most exciting gold stories in Canada. Northern Superior Resources is a rare gem that could shine brighter than many others.
#1 The next Canadian Malartic
Attention, investors! This is your chance to consider getting involved on the ground floor of a once-in-a-lifetime opportunity where central banks keep buying gold, combined with an oppertunity to getting a do-over on Malartic. Why is that significant? The company that owned Malartic was sold for C3.9 billion! Northern Superior Resources Inc. is a junior exploration company that is poised to possibly become the next Canadian Malartic. How will they do that? It is simple, they have consolidated the area and continue to rapidly increase the size of those deposits. By owning all of those nearby deposits, Northern Superior is rapidly reaching a critical geological level where the camp could become a single large mining operation. This matters as viable ounces are worth significantly more than unviable ounces, hence the consolidation strategy.
If you’re looking for a golden opportunity to invest in one of Canada’s largest and most exciting gold companies, look no further than Northern Superior Resources Inc. Northern Superior is consolidating the Chibougamau Gold Camp in Quebec, a region that has produced over 6 million ounces of gold historically. The company has discovered or acquired several impressive gold projects, including the Lac Surprise project, which is adjacent to IAMGOLD’s Nelligan project, which was the “Discovery of the Year” in 2019, and hosts a total of 5.5 million ounces[2] of gold.
Northern Superior Resources Inc. also has district scale exploration potential in Ontario, where it owns 100% of the TPK project, the largest till anomaly in North America, something that is sure to get the attention of any geologist. The TPK project has shown exceptional gold and diamond results, with drill intercepts of up to 25.9 grams of Gold per tonne over 13.5 meters and a boulder carrying 727 grams of Gold per tonne. The company recently obtained its drilling permit for this asset and has indicated its intention of spinning out this asset into a new company to accelerate its development. If TPK were to repeat historical exploration success, directly or indirectly, the shareholders of Northern Superior would greatly benefit.
Northern Superior Resources Inc. is led by a seasoned management team with decades of experience in the mining industry. Let’s take a closer look at their team.
Executive Team
Victor Cantore is the Executive Chairman of Northern Superior Resources with over 25 years of experience in the mining industry, having worked as an investment advisor, head of institutional trading and a corporate finance specialist. He has been instrumental in raising funds and negotiating deals for several mining companies, including Amex Exploration, where he serves as the President and CEO. It is worth mentioning again that he took Amex Exploration from C$0.07 to more than $3.50 in less than 2 years!
Cantore is passionate about creating value for shareholders and stakeholders, while adhering to the highest standards of environmental and social responsibility. He believes that Northern Superior Resources has the potential to become one of Canada’s premier gold producers. He is committed to advancing the projects to the next level.
Simon Marcotte is one of the most accomplished and visionary leaders in the Canadian mining industry. He has a proven track record of creating value for shareholders through his involvement in several successful exploration and development projects across various commodities. Marcotte has over 25 years of experience in the mining sector, starting his career as a Chartered Financial Analyst with CIBC World Markets, Sprott and Cormark Securities.
In 2018, Marcotte was instrumental in launching Arena Minerals Inc., a lithium exploration company with assets in Argentina. He facilitated strategic investments from Ganfeng, the world’s largest lithium producers, and also from Lithium Americas Corp. Most important to investors, he was instrumental in the price appreciation from $.05 – $.75! Arena was finally acquired by Lithium Americas Corp. in 2023.
In 2020, Marcotte founded Royal Fox Gold Inc., where he served as President and CEO until November 2022, when he orchestrated a merger with Northern Superior Resources and was appointed President and CEO of Northern Superior Resources thereafter.
Marcotte is also the founder of Black Swan Graphene Inc., a graphene manufacturing company based on a proprietary technology developed by Thomas Swan & Co. Ltd., a leading chemical company based in England. The shares of Black Swan Graphene just recently went up by 400%.
Michael Gentile is one of the most successful investors in the mining sector in Canada. He has built a fortune by identifying undervalued and overlooked opportunities in the natural resources industry; after his latest capital injection in the company, he now owns 16% of Northern Superior.
Michael, a former fund manager, has developed a reputation as a savvy and visionary investor who could spot opportunities that others missed. He invested in companies that had strong fundamentals, low valuation, high-quality assets, and growth potential. He also looked for companies that were undervalued by the market or had catalysts for appreciation.
Some of his most notable investments include:
- K92: One of the most successful mining companies in recent years; Michael acquired a major stake in the company in 2017 between C$0.45 and C$1.00. K92 now trades around C$6.00 but reached more than C$10.00 last year!
- Arizona Metals: Michael first invested in Arizona Metals around C$0.18. A little more than a year later, the stock traded at more than C$6.00 per share.
Stagflation’s Effect on Gold Prices
Gold investors have been waiting for this moment for almost 30 years, stagflation is upon us. The world is facing a serious economic dynamic. Stagflation, a situation where inflation is high and growth is slow, is absolute catnip for gold prices. Stagflation was once thought to be impossible by economists, but it happened in the 1970s, when an oil shock triggered a recession and soaring prices. This time, a step back in globalization, triggered by tension with China, and military activities in eastern Europe, are taking us down the same path.
What does this mean for investors? It means that they need to protect their wealth from the eroding effects of inflation. There is simply no better way to do that than by investing in gold, and this is why gold is already making new highs.
Gold has a long history of being a safe haven asset in times of turmoil. Gold preserves its purchasing power over time, unlike paper money that loses value as central banks print more of it. Gold also has a negative correlation with stocks and bonds, meaning that it tends to rise when they fall. Gold is therefore an ideal hedge against stagflation and market volatility.
But not all gold investments are created equal. Some are more risky and costly than others. That’s why we recommend taking a look at Northern Superior Resources, a company backed by a team with a proven track record of success.
Northern Superior Resources has a portfolio of high-quality projects in Canada, one of the most stable and mining-friendly jurisdictions in the world. The company has a strong management team with decades of experience in the industry. The company also has a low-cost structure and a healthy balance sheet, with no debt and ample cash.
In Closing – Northern Superior Resources Inc. has a diversified portfolio of gold in Ontario and Québec. The company’s value driver is its recent consolidation effort to put all of those deposits under one roof, opening the door to a single mining operation, and therefore increasing the value of those deposits. The flagship project, at least for the time being, is the Philibert Project, which has already seen more than 77,000 metres of drilling, a large part paid for by the Quebec Government, and is now about to publish a resource calculation. On its website, the Company is clear that it expects this resource publication to establish Philibert as a pillar in the Chibougamau camp. Philibert is only 9km away from Nelligan, so everyone will be quick to combine the size of those 2 deposits together and see the real value of this camp. The company also owns the Ti-pa-haa-kaa-ning (TPK) gold property, which has shown significant mineralization in several drill holes and the company indicated its intention to proceed to a spin out, which could also be an important catalyst for investors.
Northern Superior Resources Inc. is committed to creating value for its shareholders by advancing its projects to the next stage of development. The company has a strong financial position, having recently raised $5M with strong participation from insiders. The company also has a loyal shareholder base including several large institutional investors.
Don’t miss this opportunity to invest in one of the best gold exploration stories in the market. Northern Superior Resources offers you a chance to profit from the coming gold boom while protecting your wealth from stagflation.
Remember, just on of these catalysts could make SUP explode but there are three catalysts: #1 The Next Canadian Malartic #2 The Executive Team #3 Stagflation and Its Effect on Gold Prices.
Don’t miss this chance to take a look at one of the most exciting gold stories in Canada. Northern Superior Resources is a rare gem that could shine brighter than many others.
Act now before it’s too late.
Disclaimer
This Article contains forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. When used in this document, the words “may”, “would”, “could”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” and similar expressions are intended to identify forward-looking statements. Should one or more of these risks and uncertainties occur or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, or expected. This article is not intended to be a solicitation to buy or sell securities and readers are cautioned to consult their own financial advisors before doing so.
Small Cap Exclusive owned by King Tide Media has been hired by Northern Superior Resources Inc. for a period beginning on March 20th, 2023 to publicly disseminate information about (SUP) via website and email. We have been compensated up to $50,000 USD to profile SUP. Full Disclaimer
Now or Never: NLST Added Another 21% Late Friday Gains +244% YTD
In the last hour of the trading week last week, Friday April 21, 2023, the stock price of our favorite long-term play, (OTC: NLST) Netlist, Inc., shot up over 31% off the day’s lows, hitting a high of $4.21 on the day.
On what began as a relatively slow day of trading, NLST’s spike in share price would’ve seemed to have come out of nowhere. However, for us, and for those of you who’ve been following us for YEARS now, were pretty sure why. And, we weren’t at all surprised…
Rather, we felt vindicated because we FIRST alerted you all to NLST all the way back in 2021-2022 and we’ve been posting updates about it ever since.
See Exhibit 1-6
July 07, 2021: smallcapexclusive.com/netlist-inc-nlst-stock-soars-140-in-a-month-more-to-come/
July 21, 2021: https://smallcapexclusive.com/netlist-inc-nlst-stock-rockets-1100-ytd-will-it-hit-20/
August 11, 2021: smallcapexclusive.com/will-netlist-inc-otcmktsnlst-stock-come-back-after-the-recent-fall/
January 2, 2022: smallcapexclusive.com/netlist-nlst-is-ready-to-take-off/
February 22, 2022: smallcapexclusive.com/netlist-nlst-stock-price-is-consolidated-and-ready-for-a-run/
April 4, 2022: smallcapexclusive.com/netlist-nlst-stock-price-is-consolidated-and-ready-for-a-run/
The Catalyst
So, what caused the 30% pop late last week? Enter tech giant Samsung.
Netlist sued Samsung in 2021, alleging Samsung memory products used in cloud-computing servers and other data-intensive technology infringe its patents.
Netlist said its innovations increase the power efficiency of memory modules and allow users to “derive useful information from vast amounts of data in a shorter period of time.”
A Netlist attorney told the jury that Samsung took its patented module technology after the companies had collaborated on another project, according to a court transcript and were asking the jury for $404 million in damages.
Samsung had argued that the patents were invalid and that its technology worked in a different way than Netlist’s inventions.
The case is Netlist Inc v. Samsung Electronics Co, U.S. District Court for the Eastern District of Texas, No. 2:21-cv-00463.
With that valuable piece of context in mind, and over an hour after markets closed last week, it was announced that Samsung was hit with a $303 million jury verdict computer-memory patent lawsuit that the tech company had been trying to keep quiet.
However, and as longtime readers of this blog should know, the company that WON the lawsuit was none other than Netlist Inc, NLST.
April 21, 2023 5:19pm
Samsung hit with $303 million jury verdict in computer-memory patent lawsuit
(Reuters) – Computer-memory company Netlist Inc convinced a federal jury in Texas on Friday to award it more than $303 million for Samsung Electronics Co’s infringement of several patents related to improvements in data processing.
The Jury determined that Samsung’s “memory modules” for high-performance computing willfully infringed all five patents that Netlist accused the Korean tech giant of violating.
Please Read The Full Article: https://finance.yahoo.com/news/samsung-hit-303-million-jury-211918301.html
First of all, I can’t believe that the title of the news story left was written in the negative “Samsung hit with $303 million jury verdict” and left out the all important fact of WHICH COMPANY WON the lawsuit, when it very easily could’ve been included. These are the kinds of “half truths” that you will not find in my writing.
To cover the WHOLE TRUTH, the title should’ve been something like this:
“‘David VS Goliath:’ Netlist Inc. Awarded with $303 million jury verdict from Samsung in tech patent lawsuit”
You see how my hypothetical title gives MORE information than the actual title about the event?… This way, the title gives the context of the court case between the nimble Netlist and goliath that is Samsung. But, more importantly, it identifies the winner of the lawsuit.
Anyway, I apologize for the tangent. Getting back to NLST…
Why NLST Is A Long-Term Play
While their victory over Samsung was the catalyst behind the 30% pop late last Friday, the court case itself has been an ever present obstacle keeping NLST from moving higher. However, and in SPITE of the court case, NLST had still tallied up TRIPLE DIGIT GAINS of 244% YTD (year to date.)
Now, those are the types of gains that gave us the green light to tell literally everyone, including our own mothers’, about this long term play because, as many of you know, the essence of long term technical analysis is: higher highs; higher lows.
If you see a series of higher highs and higher lows in at least a quarter (3 months) of trading then you’re probably looking at a really solid long-term play to invest in.
Well, since the end of January 2023, we’ve seen a series of higher highs and higher lows for NLST. Share price appears to have found support at around $3.50, which is a level that has acted as resistance in the past. Put simply, higher highs; higher lows.
Why now?
For a tech giant like Samsung, a lawsuit such as the one with NLST is like a hiccup; uncomfortable for a moment but a totally normal part of the human experience. So, to Samsung, the $303 Million hit was just the cost of doing nefarious business… For Netlist, on the other hand, the lawsuit was like an all consuming black hole of time and money.
In other words, with the jury verdict determined, NLST can start turning more of its resources and attention back to what it does BEST. Back to doing what NOT EVEN SAMSUNG could do.. Which is exactly why Samsung infringed on NLST’s patents in the first place…
Ladies and gents, think about that for 2 seconds…
Netlist does something so complex and so much BETTER than Samsung that the tech giant felt it was necessary to WILLFULLY INFRINGE on several of NLST’s patents!
THAT is why it’s now or never for the shares of NLST… Because they’ve overcome the primary obstacle stopping them from being a household name like Nvidia or Oracle.
The only thing that can stop NLST now is… Not much…
That said, for those of you who are new here or who’ve missed the original alert AND its subsequent FIVE updates then we HIGHLY recommend that you get up to date as soon as possible (links above) because, if the last 30 minutes of trading last week is any indicator of what a post jury verdict Netlist looks like then the NLST train to greener pastures is leaving the station.
All aboard!
Disclaimer
Disclaimer
Small Cap Exclusive, owned by King Tide Media, has not been hired to publicly disseminate information about NLST via website, email, or SMS. King Tide Media has not been compensated to profile NFTG. A member of Small Cap Exclusive does own shares in NLST, purchased in the open market.
Why NASDAQ: AMPG Is An ‘Under The Radar’ Juggernaut You NEED To Know About
After combing the NASDAQ exchange for weeks, we think we found a true juggernaut in the Communication Equipment Industry. The kicker… As of April 20, 2023, it’s trading at around the low low price $3.20 per share. The Company is Amplitech Group Inc. (NASDAQ: AMPG) and we think you NEED to know about this one BEFORE it becomes a household name.
Alright, without further adieu, let’s get started.
Company Details
- Stock Details
- Ticker Symbol: AMPG
- Exchange: NASDAQ
- Location: United States
- Founded: 2002
- Industry: Communication Equipment
- Sector: Technology
- Employees: 34
- CEO Mr. Fawad A. Maqbool
- Website: https://www.amplitechinc.com/
AmpliTech designs, develops, and manufactures custom and standard state‐of‐the‐art RF components for the Commercial, SATCOM, Space, and Military markets. These designs cover the frequency range from 50 kHz to 40 GHz Eventually, offering designs up to 100 GHz. AmpliTech also provides consulting services to help with any microwave components or systems design problems.Our growth has come about because we can provide complex, custom solutions. Therefore, AmpliTech is committed to providing immediate responses to any custom requirements that are presented to us. AmpliTech, Inc. has developed and supplied LNAs to Fortune 500 companies, the Military and Government Agencies such as:
- Lockheed Martin
- NASA
- L3 Communications
- Boeing
- Northrop Grumman
- Raytheon
- Government of Israel
Think this sounds like any one of the other hundreds of small-cap companies trying to make a name for themselves without any financial backing, eh?… Well, think again because AMPG has a market cap of $30.72 million. The enterprise value is $21.76 million. In fact, in the last 12 months, AMPG had revenue of $19.39 million and -$677,107 in losses. Meaning, Their FY 2022 results BEAT Revenue Guidance and Reports Record 267% YoY!
BUT THAT’S NOT ALL!
AMPG Highlights
Fundamentals:
- Financial Position: AMPG has a current ratio of 12.08, with a Debt / Equity ratio of 0.16.
- Income Statement: In the last 12 months, AMPG had revenue of $19.39 million
- Balance Sheet: The company has $13.54 million in cash and $4.67 million in debt, giving a net cash position of $8.87 million
2022 Earnings:
- In the last 12 months, AMPG had revenue of $19.39 million and -$677,107 in losses.
- AmpliTech Reports FY 2022 Results; Beats Revenue Guidance and Reports Record 267% YoY Annual Revenue Increase to $19.4 Million
Analyst Forecast:
- The consensus rating for AMPG from 7 stock analysts is “Buy”.
- This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Stock Price Forecast:
- According to 7 stock analysts, the average 12-month stock price forecast for AMPG stock is $8.16, which predicts an increase of 155.80%.
- The lowest target is $8.08 and the highest is $8.4.
- On average, analysts rate AMPG stock as a buy.
Share Statistics:
- Float: AMPG has 9.63 million shares outstanding with a low float of only 6.75 million shares
- Short Interest: The latest short interest is 89,377, so 0.93% of the outstanding shares have been sold short.
Continue reading to get our FULL BREAKDOWN of AMPG’s Highlights.
AMPG Fundamentals
- Financial Position: AMPG has a current ratio of 12.08, with a Debt / Equity ratio of 0.16.
- Balance Sheet: The company has $13.54 million in cash and $4.67 million in debt, giving a net cash position of $8.87 million
- Income Statement: In the last 12 months, AMPG had revenue of $19.39 million
The current ratio, also known as the working capital ratio, measures the capability of a business to meet its short-term obligations that are due within a year. The ratio considers the weight of total current assets versus total current liabilities. It indicates the financial health of a company and how it can maximize the liquidity of its current assets to settle debt and payables. The current ratio formula (below) can be used to easily measure a company’s liquidity.
So, if a currently has a current ratio of 2, then it can easily settle each dollar on loan or accounts payable twice. A rate of more than 1 suggests financial well-being for the company. Well, Financial Position: AMPG has a current ratio of 12.08. Meaning, it can easily settle each dollar on loan or accounts payable 12 times over.
That said, a very high current ratio may indicate that a company has excess cash in hand. Well, after looking into it, AMPG does have cash in hand… A lot of cash in hand… $13.54 MILLION to be exact.
Saving the best for last, In the last 12 months, AMPG had revenue of $19.39 MILLION. Let’s take a closer look at how great a year it’s been for this company.
2022 Earnings
In the last 12 months, AMPG had revenue of $19.39 million and -$677,107 in losses.
AmpliTech Reports FY 2022 Results; Beats Revenue Guidance and Reports Record 267% YoY Annual Revenue Increase to $19.4 Million
March 31, 2023:
2022 Annual Revenue increases nearly 3x to $19.4M, Gross Profit increases nearly 7-fold, Gross Margin almost doubles
AmpliTech Reports FY 2022 Results; Beats Revenue Guidance and Reports Record 267% YoY Annual Revenue Increase to $19.4 Million
- Gross Profit Increases nearly 7-fold, Gross Margin Expands 2,150 basis points to 46.0%
- 2022 Annual Revenue increases nearly 3x to $19.4M, Gross Profit increases nearly 7-fold, Gross Margin almost doubles
Full Year 2022 Highlights
- Revenue increased 267% to $19,394,000 in FY’22 compared to $5,275,000 in FY’21.
- FY’ 22 gross profit grew to $8,925,000, an almost 7-fold increase from FY’ 21 gross profit of $1,293,000. The gross profit margin increased by 2150 basis points to 46.0% compared to 24.5% a year ago.
- FY’22 net loss was $677,000 compared to a FY’21 net loss of $4,759,000, a positive swing of approximately $4.1 million. The net loss includes a one-time revenue earnout of approximately $816,000 as a result of Spectrum’s beating sales expectations for the years 2021 and 2022. It is important to note that without this earnout payment, the Company would have been profitable.
- As of December 31, 2022, cash and equivalents totaled $13,290,000 and working capital was $20,331,000, which is sufficient capital for AmpliTech to fund all of its strategic growth initiatives.
- AmpliTech experienced great success at trade shows such as Satellite 2022, IMS 2022, the AOC 2022, and the APS March Meeting 2022 , achieving positive customer engagement and setting company records at each event for the number of meetings with new and existing customers.
- Customers have begun to sample AGMDC’s new MMIC chip products which have received very positive praise and feedback.
Forward-Looking Update
- MMIC chips, or ICs, have been released to customers for testing and are expected to begin generating revenue in Q2 2023.
- Management expects sustained profitability going into 2023.
- Team is increasing sales exposure through enhanced strategic partnerships with sales representatives and distributors globally.
Full Earnings Report: https://finance.yahoo.com/news/amplitech-reports-fy-2022-results-130000549.html
Now, I know what you’re thinking. The past is the past. What is AMPG going to do for me in the future?… Well, let’s see what the analyst’s forecast for the future of AMPG.
Stock Price Forecast
As if that’s not a good enough projection, according to 7 stock analysts, the average 12-month stock price forecast for AMPG stock is $8.16, which predicts an increase of 155.80%. The lowest target is $8.08 and the highest is $8.4. On average, analysts rate AMPG stock as a buy. In fact, a couple of firms have already initiated coverage of AMPG with more expected to do so as this one continues to move higher.
Analyst Forecast
The consensus rating for AMPG from stock analysts is “Buy.” This means that analysts believe this stock is likely to outperform the market over the next twelve months.
The average analyst rating for AMPG stock from 7 stock analysts is “Buy”. This means that analysts believe this stock is likely to outperform the market over the next twelve months.
February 2, 2022
Analyst Firm: Small Cap Consumer Research
Rating: Buy
Target: $5.00
July 7, 2021
Analyst Firm: Maxim Group
Rating: Buy
Target: $10
If the forecasters think AMPG is worth adding to their watchlist then we should too, right? But, what about actually buying the stock for themselves? Let’s take a look…
Insider Holdings
AMPG has 9.63 million shares outstanding with a low float of only 6.75 million shares with a meager short interest of less than 1% sold short. Of their shares, 32.99% are held by insiders, 8.68% is held by 16 different institutional investors, totalling to a little under 13% of the float.
Recent News
April 17, 2023
AmpliTech Group’s Division, Spectrum Semiconductor Materials, Inks Distribution Deal with NGK Electronic Devices, a Leading Global Semiconductor Manufacturer
AmpliTech to Become NGK’s First US Distributor of Their RF Microwave Package Products
McapMediaWire – AmpliTech Group, Inc. (NASDAQ: AMPG) a designer, developer, and manufacturer of state-of-the-art signal-processing components for satellite, 5G, and other communications networks, and a worldwide distributor of packages and lids for integrated circuit assembly, as well as a designer of complete 5G/6G systems, is proud to announce its partnership with NGK Electronic Devices, a powerhouse in the semiconductor packaging industry, to become their US distributor for NGK’s state-of-the-art RF Microwave products. This partnership marks NGK’s first distribution agreement with a US partner, presenting a significant opportunity for both parties.
Full Article: https://finance.yahoo.com/news/amplitech-group-division-spectrum-semiconductor-133000902.html
March 30, 2023
AmpliTech Records a New Benchmark at Satellite 2023 Show in Washington, D.C.
McapMediaWire – AmpliTech Group, Inc. (NASDAQ: AMPG), a designer, developer, and manufacturer of state-of-the-art signal-processing components for satellite, 5G, and other communications networks, as well as a worldwide distributor of packages and lids for integrated circuit assembly, is excited to announce an unprecedented achievement at the Satellite 2023 show held in Washington, D.C. The company recorded more than 100 meetings with executives in the satellite communications (Satcom) space – a new record for the prestigious event. Among the attendees were multiple Fortune 100 companies, top-tier research institutions, and exciting startups driving the next generation of connectivity.
Full News Article: https://finance.yahoo.com/news/amplitech-records-benchmark-satellite-2023-130000747.html
February 27, 2023
AmpliTech Group, Inc. Discusses Significance of Its State-of-the-Art Radio Frequency Components with The Stock Day Podcast
AmpliTech Group, Inc. (NASDAQ: AMPG),a designer, developer, and manufacturer of state-of-the-art signal-processing components for satellite, 5G, and other communications networks and a worldwide distributor of packages and lids for integrated circuit assembly, is pleased to announce its participation in three upcoming shows, where it will exhibit its latest technological advancements at the Satellite Show in Washington DC, at Booth #2092. AmpliTech Group is also attending the Mobile World Congress (MWC) Show in Barcelona, and the American Physical Society (APS) show in Las Vegas, to participate with key players in the 5G and Quantum Computing industries.
Full News Article: https://finance.yahoo.com/news/amplitech-showcase-latest-product-wins-141500565.html
November 7, 2023
AmpliTech Recognized by Inc. Magazine as Top 10 Most Innovative Telecom Solution to Watch
AmpliTech Group, Inc. (Nasdaq: AMPG) announced that it was recognized by Inc. magazine in its list of “Top 10 Most Innovative Telecom Solution to Watch”
Founder and CEO Fawad Maqbool stated, “It was an honor to work with Inc. Magazine on this article to discuss Amplitech Group and how we currently offer a wide range of products for 5G, Telecom, quantum computing, airline Wi-Fi, and all things wireless, starting from connectorized modules, discrete transistors, MMICs, and packages, to multi-chip modules (MCMs) and systems using multiple disciplines and processes that we see a lack of in the market. All of these products directly enable technologies such as Virtual Reality (VR), Augmented reality (AR), Telemedicine, fully autonomous vehicles, Satellite-to-phone connectivity, the Internet of Things (IoT), Internet in the sky, and much more. AmpliTech is committed to connecting humans like never before in the 21st century.”
Full News Article: https://finance.yahoo.com/news/amplitech-recognized-inc-magazine-top-210000268.html
AMPG Company Background
Developing the communication systems of tomorrow, today.
AmpliTech was founded to address the industry gap for high-performance, ultra-reliable, and extremely efficient radio frequency (RF) devices to power the communication ecosystem of tomorrow. We obsess over pushing boundaries of what can be done to increase connectivity in the sky, in space, and in your homes. The devices AmpliTech designs boast the lowest noise figures and power dissipation across all usage frequencies to offer customers in the military, Satcom, aviation, automotive, and computing industry unparalleled product specifications and user experience. As industry requirements for communication throughput, speed, and endurance grow exponentially, we strive to develop the technologies necessary to power the future of communication.
AmpliTech designs, develops, and manufactures custom leading-edge RF components for the Commercial, SATCOM, Space, and Military markets. These designs cover frequencies from 50 kHz to 44 GHz. AmpliTech also has developed new products for the 5G/6G wireless ecosystem and infrastructure with unparalleled performance. In addition to this rapidly emerging market, AMPG has also developed solutions for Quantum Computing, with cutting edge technology. We continue to blaze trails in our commitment to enable and accelerate the arrival of true 5G/6G architecture and contribute to the U.S. being the leader and first to reach the coveted position of Quantum Supremacy. Our growth has come about because we provide complex, custom solutions that our competitors shy away from. We have consistently provided the industry-leading SATCOM Low Noise Amplifier Solutions for the past 18 years and our new website showcases these products below, with its advanced search engine and listing of stock items. This allows us to provide immediate response to custom requirements, unwavering technical support and timely delivery. We will be continuing our R&D efforts to always be at the forefront of emerging technologies and using our advanced techniques and IP to provide tomorrow’s technology today, and improve everyone’s quality of life. In addition, we have the best assemblers, wirers, and technicians in the industry and can provide contract assembly of customers’ own designs. AmpliTech is in the process of scaling up its proprietary technology and design its own MMICs, subsystems, and other products to address the rapidly emerging, large volume commercial applications in the communications technology space.
AmpliTech, Inc. has a rich history in the design of microwave amplifiers and components, including a wide variety of product lines, from LNA’s (Low Noise Amplifiers) and MPA’s (Medium Power Amplifiers), to broadband telecom amplifiers for the microwave and fiber optic communications firms.
As such. we are defined by our expertise in custom designed amplifiers with special requirements such as military screening and space qualification. To provide for customers dealing with extremely low noise figure applications, we have excelled in the ever-growing cryogenic market as well. In short, all our customers agree that we provide simply the best product and services available in the industry while maintaining lower prices than most of our competitors and we do so in the most emergent of technologies on the industry landscape today. Our success is marked not only by our technical achievements, but also by an extremely respectable customer base which includes giants in the industry such as Motorola, ITT, Harris, Northrop Grumman, Raytheon, L3 Communications, Aeroflex, NASA, NIST and TRW (to name a few). Due to the achievements of its talented staff, AmpliTech has also received numerous Supplier Quality awards, including a Best Technology Award from one of the industry’s leading trade magazines. AmpliTech now trades on the NASDAQ public stock exchange under the ticker symbol AMPG which will help take our products to a broader and more global customer base, bringing cutting-edge technology to the masses and improving everyday quality of life for us all. The following are some of the many advantages that set us apart from our competition:
- Skilled and experienced Management Team
- Proven track record of performance and quality products
- Quantified IP and pending patents
- Virtual sole-source current supplier positions in various areas such as Quantum Computing, Military Avionics Equipment, High-speed SATCOM equipment, Telemetry applications
- Government GSA Award
- Strategic alignment with key vendors and customers to provide next generation products for 5G/6G. Quantum Cloud, High-speed Satellite Internet, IoT commercial markets
- Integration of Microwaves and Life Sciences to provide diagnostic and non-invasive detection systems and treatments for medical applications
- Much more!
Core Competencies
AmpliTech, Inc. offers:
- Standard state-of-the-art RF/Microwave components for the Commercial, SATCOM, Space, & Military
- markets.
- Highly customized RF/Microwave amplifiers that cover frequency ranges from 50 kHz to 100 GHz.
- Cryogenically cooled LNAs that achieve the lowest Noise Figures in the industry.
- High reliability Space-Qualified components that meet standards of excellence that no other
- manufacturer in the industry can match.
- Consulting services to provide technical support for any microwave components or systems design issues, even from other manufacturers.
Differentiator
AmpliTech, Inc. provides tangible advantages
over our competitors because:
- Superior product -even standard commercial
- units are built to MIL-883 guidelines.
- Most competitive pricing in the industry.
- Timely delivery.
- The highest possible level of customer service
- and technical support.
- We’ve developed designs for hundreds of
- customers who couldn’t find manufacturers to
- meet their stringent specs.
Key Executives
Fawad Maqbool (President and CEO (Founder) / CTO)
Mr. Maqbool has been in the microwave business for 30 years. He has a B.S.E.E. in microwave engineering and a B.S.E.E in Bio-Medical Engineering from CUNY and an M.S.E.E from Polytechnic University of New York. He founded AmpliTech in 2002 to fill the need for affordable, high quality, custom, state-of-the-art amplifiers and components. For almost 14 years as Department Head, he designed and developed state of the art amplifiers and components for MITEQ Inc., a leading supplier of microwave components and communications equipment. He then founded AmpliComm (acquired by Aeroflex, Inc. (ARXX) in 2000 to develop custom cryogenic and fiber optic amplifiers and components). Mr. Maqbool’s innovative management and design experience continues to push AmpliTech’s boundaries in microwave technology both in commercial and military markets. Mr. Maqbool has received various awards for innovative design and quality from suppliers such as Motorola, and publications such as Wireless Design and Technology magazine. AmpliTech continues to surpass it’s peers in performance, value, service, and innovation, and is poised to become the leading supplier of amplifiers and related components in the coming years.
Louisa Sanfratello (Chief Financial Officer)
Louisa Sanfratello, a CPA (Certified Public Accountant), has been a Certified Public Accountant working in numerous organizations in various industries since 1998. Her duties throughout this time and her time as an accountant for various charities and schools consisted of preparation of official financial documents as well as day-to-day financial management. Also tapped were her skills in the area of projection of cash flow and consequent requirements. Her professional career began in 1987 with the public accounting firm of Holtz, Rubinstein & CO., where she gathered two years of invaluable experience before earning her CPA and moving on to more challenging things.
Jorge Flores Chief Operating Officer
Having joined AmpliTech at the end of March in 2021, Mr. Flores brings with him over 30 years of combined Operations and Program Management experience. Prior to joining Amplitech’s executive leadership team, Mr. Flores held various leadership roles at Comtech Telecommunications, a Nasdaq listed corporation with over 2K employees and revenues of over $600M. Previous management roles included Director of Program Management Office, Business Unit Manager and Supply Line Management. Mr. Flores holds an MBA with concentration in Operations Management and Leadership from Dowling NY and, a BS in Business Administration, Major in Operations Management from NYIT.
John P. Pastore Director of Sales
Mr. Pastore has been in the microwave industry for 40 years. He has a B.S. in Business Management and has worked for many of the leaders in the RF/Microwave industry. Mr. Pastore is a hands-on professional whose experience spans over 20 years of progressive roles through which he has gained a rare blend of technical, manufacturing, customer service, and management skills and capabilities. His business savvy and deep understanding of the industry make him an extremely valuable asset to the company and an integral part of the AmpliTech team.
Trending Now: (SWAN.V) Black Swan Graphene’s Explosive Month of April
Small Cap Exclusive is always on the lookout for under the radar companies that have established a positive trend, backed by breaking news, technical analysis, fundamentals, & / or insider & institutional backing. And, we believe that Black Swan (TSXV: SWAN.V) may just be one such company that’s trending higher backed by some excellent news. Here’s what we’ve found.
Previous Trend
Starting with their previous trend, was essentially stagnant, trading at around $0.10-$0.15, for the past 6 months. However, as of March 27, 2023 a new trend started to take shape…
Trending Now: Black Swan Graphene
As of April 19, 2023: Currently trading at $0.25, shares are up over 92.30% since March 27, 2023, hitting 52 week highs 9 different times during that time.
But, is this just a coincidence or has a new trend been established for Black Swan?
Trend Catalyst
March 27, 2023: Black Swan was trading at $0.13, around where it’s been trading for the past 6 months.
- 9:07am – The Investment Industry Regulatory Organization of Canada (IIROC) put a halt on all shares of Black Swan (TSX.V: SWAN.V) for the reason of… Pending News.
- 11:45am – IIROC announced the resumption of trading for all shares of Black Swan as the news was released.
The March 27 News Release
Black Swan Graphene and Nationwide Engineering Announce Strategic Partnership, Part of an Integrated Supply Chain, to Accelerate the Adoption of Graphene-enhanced Concrete Globally.
Black Swan Graphene Inc. and Nationwide Engineering Research and Development Ltd. (“NERD”) announced that their strategic partnership was being embedded in a fully integrated supply chain which will include Arup Group Limited (“Arup”), a multinational engineering consultancy headquartered in London, United Kingdom, with 18,000 experts working across 140 countries.
News Update #1:
April 6, 2023: Black Swan stock price was trading at $0.15, up 15% since their March 27 announcement.
- News Release: Black Swan Graphene Announces Closing of Equity Swap with Nationwide Engineering Creating a Strategic Partnership, Part of an Integrated Supply Chain, to Accelerate the Adoption of Graphene-enhanced Concrete Globally
News Update #2
April 10, 2023: Black Swan was trading at $0.165, up 26% since their March 27 announcement.
- News Release: Black Swan Graphene CEO discusses concrete supply chain partnership with Nationwide Engineering
News Update #3
April 13, 2023: Black Swan was trading at $0.20, up 53.84% since their March 27 announcement.
- News Release: Black Swan Graphene Bolsters Technical and Product Development Capabilities with Appointment of Dr. Chris Herron, A Seasoned Graphene Professional, as Vice-President Research and Product Development
Positive Trend Established
April 19, 2023: Black Swan is trending higher, hitting a new 52 week high 9 times and is currently trading at $0.25, up 92.30%, since March 27, 2023.
About Black Swan Graphene Inc
Headquartered in Toronto Canada, Black Swan Graphene Inc. (“Black Swan”) (or the “Company”) (TSXV: SWAN) (OTCQB: BSWGF) (TSX.V: SWAN.V) (Frankfurt: R96) engages in the production and commercialization of patented graphene products for concrete, polymers, Li-ion batteries, and other sectors.
NFT Gaming Company (NASDAQ: NFTG) Pushing Boundaries in $300B+ Market
Imagine taking two of the hottest verticals for investors and smashing them together.
That is exactly what NFT Gaming Company NFTG has done by combining the power of the gaming industry with the endless opportunities in the NFT sector.
If you are not familiar with NFTs and the metaverse, it could be the most promising investment for astronomical growth in 2023.
Pay close attention to NFTG over the next month as we could see massive increase in average share price with this IPO.
Looking Glass Labs could be your answer for a breakout stock, The NFT Gaming Company we researched and believe with their excellent executive team and expertise they could be an answer to the noisy market. We are all awaiting the corporate leaders of this vertical to establish themselves and it is possible that NFTG is a front runner.
The NFT Gaming Company is a new public company in the red hot sector of NFTs and gaming and we couldn’t be more excited!
Our average gains at Small Cap Exclusive this year have been absolutely impressive with the average yield being 20%+, take a look at OUR LATEST ALERTS.
We’re excited, so let’s go over why I spent the last month researching NFTG stock. Then, we can go over the macros before we get into the specifics.
Company Name: The NFT Gaming Company
Ticker: NASDAQ: NFTG
Exchange: NASDAQ
Website: https://nftgco.webflow.io/
Company Summary:
NFTG is pushing the boundaries of the industry and disrupting traditional business models in the gaming sector. The NFT Gaming Company is creating a digital gaming platform that will feature both its own proprietary games and those developed and published by third-party game developers.
What is a NFT and why should you pay attention?
I’m going to give you two definitions, the first definition is filled with jargon and then I will do my best to explain the second one in lay terms.
Non-fungible tokens or NFTs are cryptographic assets on a blockchain with unique identification codes and metadata that distinguish them from each other.
Unlike cryptocurrencies, they cannot be traded or exchanged at equivalency.
This differs from fungible tokens like cryptocurrencies, which are identical to each other and, therefore, can be used as a medium for commercial transactions.
Let’s try to break that down for us simple folk.
Non-fungible tokens are called NFTs for short and they are unique, like a digital Mona Lisa and completely different from the dollar. There was only one Mona Lisa made and it carries a very real monetary value.
On the contrary, as us Americans are finding out, when you own a fungible currency, like the dollar, you can print, print, print and continue printing which in turn debases the value.
Now, let’s look at the THREE catalysts that could send NFTG into orbit!
THREE Catalysts That Every Investor Needs To Know Before It’s Too Late:
#1 Gaming Is One Of the Hottest Sectors
#2 NFTs Are In It’s Infancy With a Strong Upside for Investors
#3 Competitors Have Already Seen Explosive Gains
#1 Gaming Is One Of the Hottest Sectors
NFTG’s goal is to develop, acquire, and manage traditional digital games while incorporating new, never-before-seen methods, such as the creation and minting of non-fungible tokens (NFTs) for in-game features like skins, characters, and experiences. The combining of blockchain based NFT technology with traditional gaming elements allows users for a personal, customizable experience, like never seen before in the gaming industry.
The NFTG gaming platform is known as the Gaxos platform. With the Gaxos platform, players will have the ability to move their characters and achievements between games as NFTs. This will allow users to have more control over their in-game assets and have more unique experiences.
Initially, the company plans to start by releasing their own straightforward and enjoyable proprietary games that allow gamers to easily mint their own affordable NFTs within the Gaxos platform. These NFTs will come with unique and exclusive features that can be utilized across the network of games on the NFTG platform.
Now, let’s go over the exciting idata surrounding the gaming sector!
The market expansion is expected to make the global gaming industry worth $321 billion by 2026, according to PwC’s Global Entertainment and Media Outlook 2022-26.
The expansion is being driven by social and casual gaming after millions of people picked up their controllers to escape the boredom and isolation of COVID-19 lockdowns.
“People were looking for ways to both entertain themselves and maintain their social connections,” says Bartosz Skwarczek, co-founder and CEO of online gaming marketplace G2A.com. “Gaming has so often been painted with the wrong brush – stereotyped as being isolating and unsociable. However, the pandemic has shown this could not be further from the truth.”
Think about the above statement, “People were looking for ways to both entertain themselves and maintain their social connections,”
NFTG is combining the excitement of gaming and the addictive nature we have seen with social media platforms like Facebook now Meta.
#2 NFTs Are In It’s Infancy With a Strong Upside for Investors
This Is Just The Beginning for NFTs & NFTG, take a look at the growth projections below.
“Brooklyn, New York, Dec. 17, 2021 (GLOBE NEWSWIRE) — According to a new market research report published by Global Market Estimates, the Global Non-Fungible Tokens Market is projected to grow at a CAGR value of 185.0% from 2021 to 2026.” The full article is here.
Remember back in the day, when you received your Netflix videos in the mail? Look at where we are now! Just like Netflix had a booming start, so are the NFTs, but literally it is just the beginning.
Just back in 2020, the NFT market was $100 million, last year, 2021, $40 Billion!
#3 Competitors Have Already Seen Explosive Gains
While not strictly a gaming company, Zedge Inc. is a company that develops digital marketplaces and competitive games centered around user-generated content that allows individuals to express themselves.
Take a look at what their stock did shortly after their IPO
Investors are starving for the next Tesla, the next Meta and their attention has been focused on the Meta/NFT/Crypto verticals.
Take a look at Roblox, a multi-faceted application that provides users with a platform for playing a diverse range of games, creating their own games, and engaging with others through online chat features.
Roblox is The NFT Gaming Company biggest competitor and they integrate gaming, social media, and social commerce into a cohesive experience and brands itself as the “ultimate virtual universe”.
Take a look at their growth.
The reason we mention these stocks are because they had their post IPO runs presenting massive gains.
Now you have the opportunity to invest in a force to be reckoned with in this explosive industry combining the best of two dominant verticals for investing.
Let’s Recap the THREE Catalysts That Every Investor Needs To Know Before It’s Too Late:
#1 Gaming Is One Of the Hottest Sectors
#2 NFTs Are In It’s Infancy With a Strong Upside for Investors
#3 Competitors Have Already Seen Explosive Gains
Disclaimer
Small Cap Exclusive owned by King Tide Media has been hired by Awareness Consulting for a period beginning on March 20th, 2023 to publicly disseminate information about (NFTG) via website and email. We have been compensated up to $10,000 USD to profile NFTG. Full Disclaimer
Mainz Biomed MYNZ Receives a $25 Price Target (Possible Gains Of 272% From Current Prices)
H.C. Wainwright Price Target Here
Small Cap Exclusive has built a reputation of uncovering stocks with massive upside potential. Our research reports have uncovered some of the largest breakout stock alerts year after year.
We stand by our alerts, our 2023 alert tracker providing transparency. Click Here
Small Cap Exclusive’s much anticipated research report on Mainz Biomed is found below.
4 Catalysts That Could Send Mainz Biomed B.V. (NASDAQ: MYNZ) Soaring Past Wainwright’s $25 Price Target
#1 H.C. Wainwright Announces MYNZ is Undervalued with a Price Target of $25
#2 Technicals Reveal a Major Bounce Play Opportunity
#3 Mainz Biomed Is Generating Revenue
#4 Philanthropic Investing feels good
Before we go over the top 4 reasons, let’s get acquainted with Mainz Biomed.
Company Name: Mainz BioMed
Ticker: MYNZ
Exchange: NASDAQ
Website: https://mainzbiomed.com/investors/
Mainz Biomed Company Summary
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert, an accurate, non-invasive, and easy-to-use early detection diagnostic test for colorectal cancer.
ColoAlert is currently marketed across Europe with an FDA clinical study and submission process intended to be launched in the first half of 2022 for U.S. regulatory approval.
Urgent: Pattern Detected
Small Cap Exclusive’s research department has uncovered a pattern with their news cycle.
Most investors react to a press release, however our largest breakout stock alerts have an over arching story hidden in the news cycle.
However, if you read between the lines, the press releases act as a road map to the future.
Found below is the important press releases signaling to savvy investors a future where Mainz Biomed could soar past $25.
Seeking Alpha’s research report echoes this sentiment with the quote below:
“The current data suggest that the approvals should occur. As such, I expect the share price to jump significantly.”
Our research department has provided the condensed press releases below that are pointing to the “big announcement” where massive price increases could take place in hours yielding a fortune for early investors.
We have highlighted the “road map” below where we found hidden in the press releases a foreshadowing of “the big announcement”.
We start with the announcement of March 2022 with the pivotal clinical trial design for ColoAlert concluding with the press release below, where they will begin commercialization throughout Europe. All press releases are located here.
Key Press Releases, When Will Be The “Big Announcement?”
Savvy investors have known for decades that corporations are sending messages to the trading public via press releases, can you detect the underlying message with their news cycle?
February 21, 2023
Transaction entails executing option agreements to purchase IP portfolio associated with current ColoAlert product and the novel gene expression (mRNA) biomarkers being evaluated in ColoFuture/eAARLY DETECT Studies
Announced today the execution of its option from Uni Targeting Research AS to acquire all of the previously licensed scientific intellectual property (“IP”) for its flagship product ColoAlert, a highly efficacious, and easy-to-use detection test for colorectal cancer (“CRC”) being commercialized across Europe.
Simultaneously, the Company also exercised its exclusive option with SOCPRA Sciences Sante et Humaines S.E.C. (“SOCPRA”), to outright purchase IP, including a pending patent, associated with a portfolio of novel gene expression (mRNA) biomarkers that have demonstrated ability to detect CRC lesions, including advanced adenomas (“AA”), a type of pre-cancerous polyp often attributed to this deadly disease.
Key Takeaway: Commercialized across Europe.
Mainz Biomed’s
3/21/23
Announced another deal to expand the marketing reach of its flagship ColoAlert diagnostic. This one is with Germany-based Labor Staber, a leading diagnostics services lab with over 800 employees, including almost 100 medical specialists, biologists, chemists, and other academics from various disciplines. Under the terms of the deal, ColoAlert, a highly efficacious and easy-to-use at-home screening test for colorectal cancer (CRC), will be marketed through Labor Staber’s extensive network of physicians and laboratories.
3/14/23
MYNZ share price weakness presents an opportunity to trade ahead of potential near-term catalysts. Shares dropped on Monday, possibly in sympathy with the Silicon Valley Bank fiasco. However, while MYNZ does list a Berkeley, California connection on its byline, this company is primarily based in Germany. Thus, financial exposure, if any, is more of a distraction than an MYNZ-specific event. Moreover, its significance is outweighed by the planned data releases expected over the next 90 days.
Remember, all deposits have been guaranteed by the U.S. Government and made available Monday morning. Hence, investors shouldn’t expect disruption to cash flow, which is the lifeblood of biotech. In other words, everything at MYNZ has stayed the same. And with contagion the likely cause of its share price decline, paying attention to MYNZ’s fundamentals and potential catalysts in the crosshairs exposes an opportunity worth seizing.
February 15, 2023
Continued roll-out in Europe with onboarding of new lab partners
Announced today the establishment of commercial partnerships for ColoAlert with Marylebone Laboratory (Marylebone Lab LTD) and Instituto de Microecologia, two leading independent laboratories covering England and Spain.
ColoAlert, Mainz Biomed’s flagship product, a highly efficacious and easy-to-use, at-home detection test for colorectal cancer (CRC), is currently being commercialized across Europe and in select international markets via a differentiated business model of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility.
Key Takeaway: Covering England & Spain.
January 18, 2023
Patient Access Initiative Addresses €1 Billion Annual Market in Germany
Announced today the launch of a corporate health program in Germany for ColoAlert, its highly efficacious and easy-to-use screening test for colorectal cancer (CRC) being commercialized across Europe and in select international territories. As a start, ColoAlert has been integrated into BGM (“betriebliches Gesundheitsmanagement”), a corporate health network providing services to employees at forty-eight of the fifty largest companies in Germany[1].
Key Takeaway: Germany
November 15, 2022
MAINZ BIOMED ANNOUNCES U.S. EXTENSION OF COLOFUTURE STUDY TO EVALUATE INTEGRATION OF NOVEL MRNA BIOMARKERS INTO COLOALERT
Announced today the initiation of eAArly DETECT, its U.S. extension of ColoFuture, the Company’s European feasibility study evaluating the integration of a portfolio of novel gene expression (mRNA) biomarkers into ColoAlert, Mainz’s highly efficacious, and easy-to-use detection test for colorectal cancer (CRC) being commercialized across Europe and in select international territories. ColoFuture/eAArly DETECT are multi-center studies assessing the potential of these biomarkers to identify advanced adenomas, a type of pre-cancerous polyp often attributed to CRC.
Key Takeaway: USA
August 16, 2022
ColoAlert to be marketed through Dante’s extensive database and sold via its region-specific, ecommerce websites
Announced today the formal commencement of ColoAlert’s consumer commercial program in Italy and the United Arab Emirates (UAE). ColoAlert is Mainz’s flagship product, a highly efficacious and easy to use, at-home detection test for colorectal cancer (CRC) currently being commercialized across Europe and select international markets.
Key Takeaway: Consumer commercial program in Italy and the United Arab Emirates
March 31, 2022
MAINZ BIOMED COMPLETES SUCCESSFUL PRE-SUBMISSION PROCESS WITH THE U.S. FDA FOR COLOALERT’S PIVOTAL CLINICAL TRIAL
announced today that it has received supportive feedback from the U.S. Food & Drug Administration (FDA) on the Company’s pre-submission package profiling the potential pivotal clinical trial design for ColoAlert, its highly efficacious, and easy-to-use detection test for colorectal cancer (CRC). As Mainz prepares to launch ColoAlert’s pivotal clinical trial, the Company is also pleased to announce the formal commencement of its reimbursement process for ColoAlert by scheduling an initial meeting with The Centers for Medicare and Medicaid Services (CMS) in April 2022.
Key Takeaway: pivotal clinical trial design for ColoAlert
December 7, 2021
At-home Colorectal Cancer Diagnostic Test Now Available Online in Germany
Mainz Biomed announced the launch of ColoAlert.de, an ecommerce store providing Germans direct access to its ColoAlert colorectal cancer (CRC) screening test. German residents unable to obtain timely CRC screening via in-person physician visits, will be able to order ColoAlert directly to their home and receive highly accurate results within a maximum of nine working days.
Key Takeaway: Cancer Diagnostic Test Available Online In Germany
DECEMBER 14th, 2021
Mainz to co-brand ColoAlert with GANZIMMUN Diagnostics, one of the largest stool analysis labs in Germany with their 5,500 labs.
Mainz Biomed announced a partnership with leading diagnostics laboratory GANZIMMUN Diagnostics AG (GD), one of Europe’s leading laboratories for preventive and complementary medicine, for the commercialization in Germany of ColoAlert, Mainz’s unique, highly efficacious, and easy-to-use detection test for colorectal cancer.
Key Takeaway: 5,500 labs in Germany
Before we reveal “the big announcement” we are all waiting for MYNZ to release let’s review the methodical international network they are creating in the press releases above.
All the while Wall Street is dead asleep. That is exactly what Small Cap Exclusive has built it’s reputation on, the deep dive research delivered direct to our subscribers inbox before volume comes pouring in.
Early investing is where Warren Buffet created his wealth and we take pride in helping retail traders have the same edge as Berkshire.
Let’s review our catalysts now before we go over what we believe is “the big announcement” that will catapult MYNZ to record breaking gains.
The 4 Catalysts That Could Send Mainz Biomed B.V. (NASDAQ: MYNZ) To Wainwright’s $25 Price Target
#1 Undervalued Presenting Massive Upside Potential
#2 Technicals Reveal a Major Bounce Play Opportunity
#3 Mainz Biomed Is Generating Revenue
#4 Philanthropic Investing feels good
#1 Undervalued Presenting Massive Upside Potential
Lets start of with the upside potential, H.C. Wainwright has issued a price target of $25 HERE
From the current PPS that is a 270% gain! Savvy traders, Pay attention!
Mainz Biomed has a Market Cap of $121 Million but when you look at other companies that are in the space, you can see the value in this diamond in the rough.
We are very excited to see this kind of potential priced at such a low PPS and with a very small float at 12 Million shares outstanding.
Furthermore, Mainz plans on starting the FDA process shortly after their public listing. Recent FDA guidance recommends colorectal cancer screening for everyone over the age of 45, which translates to a market potential of over 52 million tests per year. 1
Can you imagine what will happen to the price per share of MYNZ when they get approved? Let’s look at one of their competitors to see what actually did happen!
Take a look at Mainz Biomed’s competitor Exact Sciences Corporation NASDAQ
Today, the top non-invasive colorectal screening test technology is manufactured by Exact Sciences (NASDAQ:EXAS), which is a perfect success story that Mainz BioMed is currently seeking to recreate. EXAS is valued at $17 BILLION and trades at $60 PPS!
Could you imagine if MYNZ is trading at those PPS in the near future? That would be almost 1,000% gains, like turning $10,000 into $100,000.
We do apologize, we tend to get excited about companies that are showing massive potential in a philanthropic industry. Invest and possibly make money while saving lives, it’s the cornerstone of the capitalism that Adam Smith promoted.
Did you see the EXAS’ share price back in 08’ it fell to less than one dollar. Essentially, investors were basically saying Exact was worthless. But in June 2009, an announcement of a mutual collaboration and licensing agreement between Exact Sciences and the Mayo Clinic turned the company’s fortunes around.
Worth mentioning again, hint hint, “In June 2009, an announcement of a mutual collaboration and licensing agreement between Exact Sciences and the Mayo Clinic turned the company’s fortunes around.”
However, it was in 2014 when the FDA approved Cologuard for use as a non-invasive colorectal cancer screening test, and the test’s inclusion in multiple national guidelines that truly made the stock take off.
Hmm… Isn’t Mainz seeking FDA approval! See the correlation? I do and you should too.
For investors of EXAS who got in as recently as mid-2016 have already seen their investment grow nearly 20x in just over 5 years. Today it’s worth nearly $17 billion USD.
20x Returns, that $10,000 would be $200,000
Here is the kicker, Mainz Biomed’s ColoAlert is designed to be easier to administer than Exact Sciences ColoGuard, more accurate than FIT, and much less invasive than a colonoscopy. This is truly cutting edge medical testing at a fraction of the PPS of Exact Science.
MYNZ other competitor is Genescopy a privately help company making some moves
The reason I mention Geneoscopy is because this story is relevant, take a look at the investment level, $100M++!
Geneoscopy Inc. is a life sciences company focused on the development of diagnostic tests for gastrointestinal health, announced November 17th the closing of a Series B financing, raising a total of $105 million through a combination of debt and equity.
The round is led by previous investors Lightchain Capital and NT Investments. Other investors in the round include Morningside Ventures, Labcorp, Cultivation Capital, BioGenerator Ventures, and Innovatus Capital Partners. HERE
That is an example of just how large this industry is and how much money is available to fund it. It’s cancer and it has affected almost everyone in one way or the other.
#2 Mainz Biomed B.V. (NASDAQ: MYNZ) Chart Looks Amazing, for a bounce play!
Amidst the massive international stock market pull back, MYNZ PPS has been reduced by almost 50% and has created a clear consolidation pattern. See below
This is where Small Cap Exclusive shines! We issue research reports uncovering massive upside potential. There is a clear bottom in October of last year with a 30% run, then pulls back and consolidates again. We have seen this pattern over and over again and this stock should explode once the big announcement is made.
It is important to note, that MYNZ has created a stable base over the last 6 months reducing the downside risk, this is the exact point we issue research reports. Reduced risk with massive upside potential.
#3 Mainz Biomed B.V. Is Generating Revenue
ColoAlert has received CE accreditation and is approved for sale in Europe.1 European sales will provide near-term revenue potential, while they prepare for entry into the US market. Just last month, Mainz Biomed announced the launch of ColoAlert.de, an ecommerce store providing Germans direct access to its ColoAlert colorectal cancer (CRC) screening test.
This is significant, DTC (direct to consumer) test to see if you have cancer which will allow you to catch it early and have a 90% survival rate. However, only about 4 out of 10 colorectal cancers are found at this early stage. When cancer has spread outside the colon or rectum, survival rates are lower.
ColoAlert is designed for profitability, rapid commercial uptake, and broad consumer acceptance. The fact that Mainz Biomed is generating revenue in Europe and will be entering the US market with FDA approval is a massive sign for things to come. Make sure you keep MYNZ on your watchlist because the potential is substantial.
#4 Philanthropic Investing – possibly turn an amazing profit while helping people
It is rare for investors to be able to possibly have a home run return on an investment while helping to alleviate senseless deaths with the 2nd most deadly form of cancer.Colorectal cancer is the 2nd most lethal cancer in the US, but also highly preventable; with early detection providing 5-year survival rates above 90%. However, only about 4 out of 10 colorectal cancers are found at this early stage. When cancer has spread outside the colon or rectum, survival rates are lower.
90% survival rate if detected early, guess what, ColoAlert detects early stage colon cancer. There is a solution and it is ready to come to market in the USA with FDA approval.
Why is Mainz Biomed your cake and icing for investors?
-
- ColoAlert Holds Potential as a Blockbuster Early Detection Test for Colorectal Cancer. Far less senseless deaths in regards to colon cancer!
- Mainz BioMed protects its intellectual property through trade secrets to control all critical reagents, processes and formulations. Protecting intellectual property is important for market capitalization!
- Mainz Biomed MYNZ is developing proprietary genetic testing methods for pancreatic cancer. Once the distribution channel is developed, offering multiple products creates more than one revenue stream!
- Non-invasive test, which can be taken at home, with rapid response of 92% specificity and 85% sensitivity. Designed to be easier to administer than Exact Science’s ColoGuard, more accurate than FIT, and much less invasive than a colonoscopy.
We have presented the necessary research and now we are ready to unveil what our research is pointing to, “the big announcement”.
On December 6, 2022 MYNZ announced approval from an independent Institutional Review Board (IRB) for the protocol ReconAAsense, the Company’s U.S. pivotal study to evaluate the clinical performance of its highly efficacious and easy-to-use detection test for colorectal cancer (CRC).
Mainz Biomed has been conducting this study for over a year, which will form the basis of the data package to be submitted for review by the U.S. Food and Drug Administration (FDA) to achieve marketing authorization.
ReconAAsense is a prospective clinical study that will include approximately 15,000 subjects from 150 sites across the United States. The study objectives include calculating sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) in average-risk subjects for CRC and advanced adenomas (AA).
We believe the studies will come back positive and will be released soon. Mainz Biomed has been methodically making strategic moves that act as a harbinger of things to come.
We are already diving deeper into this for our second research report on the impact on PPS when the announcement comes. To receive this exclusive report before our publication, sign up below.
Let’s recap why Mainz Biomed MYNZ could be, THE massive breakout of 2023!
#1 MYNZ is Undervalued
#2 Mainz Biomed B.V. (NASDAQ: MYNZ) Chart Looks Amazing!
#3 Mainz Biomed B.V. Is Generating Revenue
#4 Philanthropic Investing feels good
It is a rare opportunity in this world to have this kind of investment opportunity while also funding the act of saving lives. This is an easy fix, detect the 2nd most dangerous form of cancer early and you have a 90% survival rate. ColoAlert is the answer, we just need to stop what we are doing and place it on your watchlist, today!
Happy Trading and remember, never try to catch a falling knife!
Condensed Disclaimer
Small Cap Exclusive has been hired by Awareness Consulting for a period beginning on February 24, 2023 to publicly disseminate information about (MYNZ) via website and email. We have been compensated $116,000 USD to profile MYNZ for one month. We will update any changes to our compensation. Full Disclaimer
FSD Pharma Inc. (HUGE) Is Bullish On ALL 19 Technical Indicators
FSD Pharma Inc. HUGE stock could be heading to the moon, look at this chart below!
Top 3 Reasons To Turn Your Attention To (NASDAQ: HUGE) Right Away:
#1 All Technical Indicators & The Chart Are BULLISH
#2 Canada Greenlighted Phase 1 Trial for Multiple Sclerosis
#3 The Stock Has A History Of Big MOVES
FSD Pharma Growing Systems Company Summary
Company Name: FSD Pharma Inc.
Ticker: HUGE
Exchange: NASDAQ
Website: https://fsdpharma.com/
Company Summary: FSD Pharma, Inc. is a specialty biotech pharmaceutical research and development company. It focuses on developing over time a robust pipeline of FDA-approved synthetic compounds targeting the end cannabinoid system of the human body to treat certain diseases of the central nervous system and autoimmune disorders of the skin, GI tract, and the musculoskeletal system. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.
No need to really discuss this in great detail, this is incredibly rare to have all 19 technical indicators on Yahoo and Market Watch agreeing that this stock is BULLISH.
There are no Guarantees in the stock market BUT this is as close as we have ever seen!
Seeking Alpha wrote an amazing article on FSD Pharma Inc. (NASDAQ:HUGE) and we include an excerpt from it below.
- “The shares of Canadian biotech FSD Pharma (NASDAQ:HUGE) rose for the fourth consecutive session on Tuesday after announcing that Canada greenlighted its Phase 1 trial for multiple sclerosis candidate LUCID-21-302.
- Issuing a No Objection Letter (NOL), Health Canada has granted the regulatory nod to start the first-in-human clinical trial for LUCID-21-302 in the country, FSD (HUGE) said without detailing the estimated timeline for the study.
- “We will continue to work with Health Canada and other regulators worldwide to complete clinical investigations as soon as we can,” Chief Executive Lakshmi Kotra remarked.
- Preclinical studies have indicated the potential of LUCID-21-302 in the prevention of myelin degradation, which is believed to result in neurogenerative diseases such as MS, where there is damage to the myelin sheath in neuronal cells.
- The Toronto-based pharma announced in September that the US and Canadian regulators cleared its mid-stage trial for FSD201 to treat a form of pain caused by the abnormal functioning of the body’s mast cells called idiopathic mast cell activation (IMCA) syndrome.“
Press Release Below
February 7th 2023
TORONTO–(BUSINESS WIRE)–FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announces the receipt of a No Objection Letter (“NOL”) from Health Canada regarding the Company’s proposed Phase 1 clinical trial of LUCID-21-302 (“Lucid-MS”), a novel drug candidate for the treatment of Multiple Sclerosis (“MS”). The NOL provides FSD Pharma with regulatory approval to move forward with the clinical trial in Canada.
Look at this BEAST, exploding from $1.36 to $4.09 representing 200% gains!
WOW, $17 to $154 representing almost 1,000% gains. Furthermore, the fact that it was at $154 pre-covid and supply chain difficulties reveals the MASSIVE potential of this burgeoning Wall Street darling!
Let’s recap!
Top 3 Reasons To Turn Your Attention To (NASDAQ: HUGE) Right Away:
#1 All Technical Indicators & The Chart Are BULLISH
#2 Canada Greenlighted Phase 1 Trial for Multiple Sclerosis
#3 The Stock Has A History Of Big MOVES
Happy Trading!
DISCLAIMER
Small Cap Exclusive is owned and operated by JBN PARTNERS LLC, which is a US based corporation has not been compensated for profiling HUGE. We own ZERO shares in HUGE.
Best Stocks of 2023 Best NASDAQ Stocks, delivered to YOU
Delivering the best NASDAQ stocks of 2023 yielding on average double digit gains.
We believe in transparency!
We post every pick so you can feel confident in our 💎 featured breakout alerts.
Small Cap Exclusive’s Best NASDAQ Stocks of 2023:
Best Stock of 2023 Avalon GloboCare Corp. (ALBT)
Ticker: ALBT
Corp Name: Avalon GloboCare Corp.
Date Of Alert: March 6th
Alert Price: $2.14
Date Of High: March 6th
High After Alert: $3.87
Gain/Loss: Gain of 81%
Best Stock of 2023 Mainz Biomed (MYNZ
Ticker: MYNZ
Corp Name: Mainz Biomed
Date Of Alert: February 15th
Alert Price: $7.35
Date Of High: February 15th
High After Alert: $7.50
Gain/Loss: Gain of 17%
Best Stock of 2023 FSD Pharma Inc. (HUGE)
Ticker: HUGE
Corp Name: FSD Pharma Inc.
Date Of Alert: February 9th
Alert Price: $1.44
Date Of High: February 11th
High After Alert: $1.68 (52 Week High)
Gain/Loss: Gain of 17%
Best Stock of 2023 MDJM Ltd (MDJH)
Ticker: MDJH
Corp Name: MDJM Ltd
Date Of Alert: February 3rd
Alert Price: $1.80
Date Of High: February 3rd
High After Alert: $2.10
Gain/Loss: Gain of 17%
Best Stock of 2023 Uranium Royalty Corp. (UROY)
Ticker: UROY
Corp Name: Uranium Royalty Corp.
Date Of Alert: February 1
Alert Price: $2.80
Date Of High: February 1st
High After Alert: $2.93
Gain/Loss: Gain of 5%
Best Stock of 2023 Stock GoldMining Inc. (GLDG)
Ticker: GLDG
Corp Name: GoldMining Inc.
Date Of Alert: January 31st
Alert Price: $1.15
Date Of High: February 1st
High After Alert: $1.24
Gain/Loss: Gain of 7%
Best Stock of 2023 Stock Avalon GloboCare Corp. ALBT
Ticker: ALBT
Corp Name: Avalon GloboCare Corp
Date Of Alert: January 8th
Alert Price: $4.01
Date Of High: January 9th
High After Alert: $4.47
Gain/Loss: Gain of 11%
Best Stock of 2023 Stock Clearmind Medicine Inc. CMND
Ticker: CMND
Corp Name: Clearmind Medicine Inc.
Date Of Alert: January 4th
Alert Price: $3.26
Date Of High: January 9th
High After Alert: $5.10
Gain/Loss: Gain of 56%
Best NASDAQ Stock Kaival Brands Innovations Group, Inc. (KAVL)
Ticker: KAVL
Corp Name: Kaival Brands Innovations Group, Inc.
Date Of Alert: December 6th
Alert Price: $.98
Date Of High: December 8th
High After Alert: $1.10
Gain/Loss: Gain of 11%
Best NASDAQ Stock LuxUrban Hotels Inc. (LUXH)
Ticker: LUXH
Corp Name: Kaival Brands Innovations Group, Inc.
Date Of Alert: November 30th
Alert Price: $1.40
Date Of High: January 11th
High After Alert: $1.80
Gain/Loss: Gain of 28%
Our commitment to delivering the best stocks of 2023:
Facebook LINK
How do we deliver the best stocks of 2023?
Fast & Actionable Alert Delivery
As soon as a potential trade presents itself, our team works to send out the trade alert quickly, delivering high quality alerts for traders and investors.
Unlock Your Best Trading Potential
The best NASDAQ Stocks are more accessible than ever before. Get started with just a smart phone in your hand, use the tools we provide to enhance your trading level.
Top Picks From Curated Watchlists
We spend our time scanning the market and analyzing our watchlists looking for the best trade ideas to alert our members. Our team does this so you don’t have to!
Partial Disclaimer
Small Cap Exclusive is owned and operated by JBN PARTNERS LLC, which is a US based corporation has been compensated $5,000 by Life water Media on Jan 9 for ALBT, $5,000 from Life Water Media for profiling CMND, KAVL on Dec 6 paid $8,000 by Awareness Consulting. LUXH – Nov 30 – not compensated. We own ZERO shares in any above mentioned stock.
We are paid advertisers, also known as stock touts or stock promoters, who disseminate favorable information (this “Article”) about publicly traded companies (the “Profiled Issuers”).
We publish the Information on our website, smallcapexclusive.com/ and in newsletters, text message alerts, audio services, live interviews, featured “research” reports, on message boards and in email communications for specific time periods that are agreed upon between us and the Profiled Issuer and / or third party paying us. Our publication of the Information is known as a “Campaign”. This information may be sent to potential investors at different times that are minutes, hours, days or even weeks apart. Typically, the trading volume and price of a Profiled Issuer’s securities increases after the information is provided to the first group of investors. Therefore, the later an investor receives the Information, the more likely it is that he will suffer trading losses if they purchase the securities of a Profiled Issuer late in a Campaign.